Other non-current assets - Summary (Details) - EUR (€) |
Dec. 31, 2025 |
Dec. 31, 2024 |
Dec. 31, 2023 |
|---|---|---|---|
| Other non-current assets | |||
| Non-current restricted cash | € 1,759,000 | € 1,985,000 | |
| Non-current portion of upfront payment to NovAlix | 2,580,000 | ||
| Non-current portion of advance related to the NovAliX transaction | 2,877,000 | ||
| Other non-current assets | 1,200,000 | 1,266,000 | |
| Total other non-current assets | € 2,959,000 | € 8,708,000 | |
| Collaboration agreement for drug discovery and research operations [member] | |||
| Other non-current assets | |||
| Current and non-current prepayments | € 8,300,000 |